scholarly journals Anoctamin 1 (TMEM16A) is essential for testosterone-induced prostate hyperplasia

2015 ◽  
Vol 112 (31) ◽  
pp. 9722-9727 ◽  
Author(s):  
Joo Young Cha ◽  
Jungwon Wee ◽  
Jooyoung Jung ◽  
Yongwoo Jang ◽  
Byeongjun Lee ◽  
...  
Keyword(s):  
Prostatic Hyperplasia ◽  
Elderly Men ◽  
Anoctamin 1 ◽  
Prostate Hyperplasia ◽  
Prostate Epithelial Cells ◽  
Prostate Enlargement ◽  
Urinary Tract Symptoms ◽  
Interfering Rna ◽  
Lower Urinary

Benign prostatic hyperplasia (BPH) is characterized by an enlargement of the prostate, causing lower urinary tract symptoms in elderly men worldwide. However, the molecular mechanism underlying the pathogenesis of BPH is unclear. Anoctamin1 (ANO1) encodes a Ca2+-activated chloride channel (CaCC) that mediates various physiological functions. Here, we demonstrate that it is essential for testosterone-induced BPH. ANO1 was highly amplified in dihydrotestosterone (DHT)-treated prostate epithelial cells, whereas the selective knockdown of ANO1 inhibited DHT-induced cell proliferation. Three androgen-response elements were found in the ANO1 promoter region, which is relevant for the DHT-dependent induction of ANO1. Administration of the ANO1 blocker or Ano1 small interfering RNA, inhibited prostate enlargement and reduced histological abnormalities in vivo. We therefore concluded that ANO1 is essential for the development of prostate hyperplasia and is a potential target for the treatment of BPH.

scholarly journals Pharmacological Effects and Potential Clinical Usefulness of Polyphenols in Benign Prostatic Hyperplasia

Molecules ◽  
2021 ◽  
Vol 26 (2) ◽  
pp. 450
Author(s):  
Kensuke Mitsunari ◽  
Yasuyoshi Miyata ◽  
Tomohiro Matsuo ◽  
Yuta Mukae ◽  
Asato Otsubo ◽  
...  
Keyword(s):  
Benign Prostatic Hyperplasia ◽  
Molecular Mechanisms ◽  
Prostatic Hyperplasia ◽  
Pathological Conditions ◽  
Urinary Tract Symptoms ◽  
Anti Inflammatory ◽  
Lower Urinary

Benign prostatic hyperplasia (BPH) is arguably the most common benign disease among men. This disease is often associated with lower urinary tract symptoms (LUTS) in men and significantly decreases the quality of life. Polyphenol consumption reportedly plays an important role in the prevention of many diseases, including BPH. In recent years, in addition to disease prevention, many studies have reported the efficacy and safety of polyphenol treatment against various pathological conditions in vivo and in vitro. Furthermore, numerous studies have also revealed the molecular mechanisms of the antioxidant and anti-inflammatory effects of polyphenols. We believe that an improved understanding of the detailed pharmacological roles of polyphenol-induced activities at a molecular level is important for the prevention and treatment of BPH. Polyphenols are composed of many members, and their biological roles differ. In this review, we first provide information regarding the pathological roles of oxidative stress and inflammation in BPH. Next, the antioxidant and anti-inflammatory effects of polyphenols, including those of flavonoids and non-flavonoids, are discussed. Finally, we talk about the results and limitations of previous clinical trials that have used polyphenols in BPH, with particular focus on their molecular mechanisms of action.

scholarly journals Novel Surgical Treatments for Benign Prostatic Hyperplasia

2019 ◽  
Vol 2 (1) ◽  
pp. e17-e23
Author(s):  
Blessing Dhliwayo ◽  
Saheel Mukhtar
Keyword(s):  
Benign Prostatic Hyperplasia ◽  
Gold Standard ◽  
Lower Urinary Tract ◽  
Minimal Invasive ◽  
Prostatic Hyperplasia ◽  
Treatment Modalities ◽  
Elderly Men ◽  
Urinary Tract Symptoms ◽  
Surgical Treatments ◽  
Lower Urinary

Transurethral resection of the prostate (TURP) has been the gold standard for the treatment of elderly men with lower urinary tract symptoms (LUTS) caused by benign prostatic hyperplasia (BPH). However, over the last few years, advances in surgical treatment have led to the development of other treatment modalities. These innovations include convective WAter Vapor Energy (WAVE; Rezum System), prostatic urethral lift (PUL; UroLift System), Prostate Artery Embolisation (PAE) and Aquablation (AQUABEAM System). This review provides an update on these current minimal invasive surgical treatments. The evidence of their safety, tolerability and efficacy in clinical practice is reviewed.

scholarly journals Giant prostatic hyperplasia: case presentation of the second largest prostate adenoma

2021 ◽  
Vol 27 (1) ◽  
Author(s):  
Erdinc Dincer ◽  
Osman Murat Ipek ◽  
Sukran Sarikaya Kayipmaz ◽  
Burcu Hanci
Keyword(s):  
Urinary Tract ◽  
Benign Prostatic Hyperplasia ◽  
Lower Urinary Tract Symptoms ◽  
Lower Urinary Tract ◽  
Lower Extremities ◽  
Prostatic Hyperplasia ◽  
Prostate Hyperplasia ◽  
Case Presentation ◽  
Urinary Tract Symptoms ◽  
Lower Urinary

Abstract Background Benign prostate hyperplasia is one of the most common diseases in middle-aged or older men. Approximately 50% of men over 60 years old suffer from benign prostatic hyperplasia. Giant prostatic hyperplasia is defined as a prostate exceeding 500 g. In all the literature, ten case reports were published with giant prostatic hyperplasia. Case presentation In this case report, we present a 72-year-old man with edema of lower extremities. In physical examination, bilateral pitting edema of the lower extremities was detected. Serum prostate-specific antigen level was > 100.00 ng/ml. He did not have lower urinary tract symptoms. International Prostate Symptom Score (IPSS) and uroflowmetry results proved that the patient did not have lower urinary tract symptoms. Radiologic imaging revealed a huge pelvic mass behind bladder. Grade 1 hydronephrosis in the right kidney was detected, but serum creatinine value was normal. This mass was excised with open surgery. This mass was measured 1090 g, and histopathologic examination showed benign prostatic hyperplasia. The patient had no complication at the 12-month follow-up. After 5 years, prostate volume was calculated approximately 108 cc by computer tomography but still the patient did not have any lower urinary tract symptoms. Conclusion It is important to approach the retroperitoneal mass. Clinicians usually think about malignity, but sometimes that mass can be relevant with benign process. Intra-operative biopsy can help clinicians for both diagnosis and surgical approach. In this case presentation, we report a patient with one of the largest sizes of prostate gland that measured 1090 g.

Sign in / Sign up

Export Citation Format

Share Document